Diagnos Announces Upsize of Previously Announced Brokered Private Placement to $3.65M Led by Centurion One Capital

Core Viewpoint - Diagnos Inc. has announced an upsized brokered private placement due to strong investor demand, aiming to raise approximately $3,650,000 by issuing up to 12,166,667 units at $0.30 per unit [1][2]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrant allowing the purchase of one share at $0.40 for 18 months post-closing [2]. - The offering is led by Centurion One Capital Corp. as the lead agent and sole bookrunner, with proceeds allocated for regulatory affairs, product development, business development, and general corporate purposes [3]. - The offering is expected to close around December 3, 2025, subject to necessary approvals, including from the TSX Venture Exchange [5]. Group 2: Participation and Compliance - Certain insiders of the company and lead agent may acquire up to approximately 50% of the offering, which will be considered a related party transaction but is expected to be exempt from formal valuation and minority shareholder approval requirements [6]. - The units will be offered via private placement in specific Canadian provinces and the U.S. under an exemption from registration requirements [4]. Group 3: Company Overview - Diagnos Inc. is a publicly traded Canadian corporation focused on early detection of critical eye-related health issues, utilizing artificial intelligence to enhance diagnostic accuracy and improve patient outcomes globally [8].